Extended Data Fig. 2: Treatment-emergent adverse events (TEAEs) up to 3 months before and after switching to once every 2 weeks (Q2W) dosing.
From: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
TEAEs occurring in ≥20% of patients at the level of SOC and in ≥10% of patients at the level of PT in up to 3 months before or after switching to Q2W dosing are reported in the 58 patients who switched to Q2W dosing. Asterisks (*) indicate a difference ≥10% in TEAE incidence after switching to Q2W dosing. COVID, coronavirus disease; PT, preferred terms; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SOC, system organ class.
